2Vansteenkiste JF, De Leyn Pr,Deneffe GJ,et al. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer:analysis of the literarure[J]. Lung Cancer,1998,19:3-13
3Deiperre A,Milleron B,et al. phase III trial of neo-adjuvant chemotherapy in respectable stage I(except T1 No),II,IIIAnon-small cell lung cancer:the French experience[J].Proc Amer Soc Clin,1999,18:465
4Rosell R,Font A,Rifare A,et al.The role of inductiot (neoadjuvant) chemotherapy in stage III A NSCLC[J].Chest, 1996,109(5):102-106
5Orlow I, Park B, Clas B, et al. Genetic instability, response to DNA damage, and repair capacity in individuals with multiple primary non-small cell lung cancers. Lung Cancer,2005,49(Suppl 2):S21(O-54).
6Chan T, MacAulay C, Lam W, et al. Finding biomarker specific for early stages of lung cancer using SAGE data. Lung Cancer,2005,49(Suppl 2):S8(O-014).
7Hirano T, Ohira T, Suga Y, et al. Quantitative proteomic exploration of biomarkers for early detection of adenocarcinoma of the lung. Lung Cancer,2005,49(Suppl 2):S179(P-247).
8Suga Y, Miyajima K, Honda J, et al. Detection of aberrant p16 promotor methylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients using real-time PCR. Lung Cancer,2005,49(Suppl 2):S84(PD-061).
9Rosell A, Rodriguez N, Lioret J, et al. Dysplasia and aberrant DNA methylation profiles in risks and lung cancer patients. Lung Cancer,2005,49(Suppl 2):S186(P-272).
10Molina J, Adjec A. Validation of a pre-selected panel of methylated genes in lung cancer as "cancer only" markers. Lung Cancer,2005,49(Suppl 2):S184(PD-266).
